Cannabidiol
Cannabidiol (CBD) is a naturally occurring, non-intoxicating phytocannabinoid — a small-molecule chemical compound isolated from Cannabis sativa.
Cannabidiol (CBD) is a naturally occurring, non-intoxicating phytocannabinoid — a small-molecule chemical compound isolated from Cannabis sativa. Unlike tetrahydrocannabinol (THC), it does not produce euphoria, which has made it attractive as a therapeutic agent. It is a lipophilic, poorly water-soluble molecule, and this physicochemical profile is central to both its pharmacology and the practical challenges of formulating it for clinical use.
CBD is studied as a pleiotropic bioactive with reported anti-inflammatory, neuroprotective, and analgesic activity, and it has been investigated across a wide range of conditions including neuropathic pain, hyperglycemia and its vascular complications, HIV-associated neurocognitive impairment, and osteoarthritis. Its effects are attributed to modulation of the endocannabinoid system together with actions on inflammatory signaling rather than to a single molecular target. A dominant theme in the current literature is CBD's poor oral bioavailability — on the order of a few percent — driven by low aqueous solubility and extensive first-pass metabolism. This has motivated extensive delivery and formulation research, including self-nanoemulsifying systems, nanostructured lipid carriers, amorphous phospholipid dispersions, and microfluidic nanoparticles, as well as co-delivery strategies pairing CBD with absorption enhancers such as piperine or with complementary bioactives like hesperetin and apigenin. Full-spectrum cannabis preparations combining CBD with THC have likewise been explored, for example as perioperative sedatives in veterinary surgery.
Where the papers sit
18 papers from the last 6 months study cannabidiol directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 1 human data · 14 preclinical · 1 unclassified
Themes 4 themes · 1 new direction
-
Oral Cannabidiol Delivery
Poor aqueous solubility and limited oral exposure are driving phospholipid complexes, SNEDDS, amorphous PVP–phosphatidylcholine dispersions and poloxamer-coated exosomes. Microfluidic formulation and mechanistic modeling are being used to tune particle size, dissolution and uptake. Fixed-dose co-delivery and nanoparticle approaches extend this work toward combination and tissue-targeted therapy. In vivo pharmacokinetics remain the main test of whether these formulation gains translate.
5 papers · 27.8%
-
Neuroinflammation and Tissue Protection
CBD is being evaluated as a regulator of neuroinflammation, cognition and tissue resilience across neurological, metabolic and cardiac injury models. Recurring endpoints include IL-6, object recognition, blood-brain barrier integrity, endocannabinoid signaling and nerve regeneration. Effects differ by comparator and disease context, with CBG and full-spectrum oils highlighting formulation and cannabinoid-specific differences. The work is moving toward mechanism-based explanations of behavioral and cardioprotective effects, but clinical relevance remains unresolved.
5 papers · 27.8%
-
Lennox-Gastaut Seizure Control
Cannabidiol treatment is moving from short-term seizure reduction toward long-term, real-world assessment in Lennox-Gastaut syndrome. Drop-seizure responses are being tracked over months in adults and across genetic subgroups. The recurring endpoint is sustained reduction in seizure burden rather than symptom change alone. How genotype, treatment duration and clinical context shape response remains the key open question.
2 papers · 11.1%
-
Others — Cannabis Therapeutic and Toxicity Studies
CBD-rich extracts and cannabis preparations are being tested across analgesia, perioperative sedation, epilepsy, glioblastoma, head-and-neck cancer and mosquito control. Reported endpoints range from cold hyperalgesia and seizure progression to apoptosis, autophagy and insect repellency. Animal and cellular models dominate, while extract composition and dosing vary substantially. The set offers no single therapeutic direction beyond broad exploration of cannabinoid effects.
6 papers · 33.3%
Cannabidiol is investigated as a mosquito-control agent rather than as a mammalian therapeutic
The adult female Aedes aegypti mosquito study treats CBD as a candidate biopesticide and repellent, outside the disease-treatment and drug-delivery roles represented elsewhere in the set. A CBD-rich hemp leaf extract caused dose-dependent adult mosquito mortality and repelled mosquitoes, whereas CBD isolate produced significantly lower mortality than the equivalent extract dose. This redirects CBD research toward vector control while also indicating that the extract’s activity cannot be attributed fully to CBD alone 42743102Sep.
Papers
The 18 papers from the last 6 months that study cannabidiol directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Oral Cannabidiol Delivery (5)
- Systems medicine-driven drug repurposing for respiratory infections: insights into the oral-gut-lung microbial axis and the therapeutic potential of cannabidiol and aspirin. Theory in biosciences = Theorie in den Biowissenschaften · 14 Nov 2026 PMID 43033373
- A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes. International journal of pharmaceutics · 25 Aug 2026 PMID 42641999
- Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol. Drug delivery · 23 Jul 2026 PMID 42487275
- Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion. AAPS PharmSciTech · 18 Jun 2026 PMID 42315741
- Microfluidics-Enabled Nanoparticle for Multiscale Synergetic Osteoarthritis Therapy. ACS nano · 9 Jun 2026 PMID 42261255
Neuroinflammation and Tissue Protection (5)
- Mechanisms by which cannabidiol promotes peripheral nerve regeneration. Neural regeneration research · 20 Oct 2026 PMID 42899815
- Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of molecular medicine (Berlin, Germany) · 18 Sept 2026 PMID 42758182
- Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease. Metabolic brain disease · 3 Sept 2026 PMID 42690466
- Differential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood-Brain Barrier Integrity in a Rat Model of Iron Overload. Neurotoxicity research · 28 Aug 2026 PMID 42663810
- Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. PloS one · 20 Jul 2026 PMID 42475352
Lennox-Gastaut Seizure Control (2)
- Long-Term Drop-Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox-Gastaut Syndrome. CNS neuroscience & therapeutics · 2 Nov 2026 PMID 42968542
- Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience. European journal of neurology · 26 Sept 2026 PMID 42798297
Others — Cannabis Therapeutic and Toxicity Studies (6)
- Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma. Medical oncology (Northwood, London, England) · 26 Oct 2026 PMID 42932045
- Toxic and repellent effects of hemp leaf extracts and cannabidiol against adult female yellow fever mosquitoes, Aedes aegypti. PloS one · 15 Sept 2026 PMID 42743102
- Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
- Cannabidiol attenuates seizure progression and recognition memory deficit induced by hippocampal HCN1 knockdown in the kindling model of epilepsy in male rats. Neuropharmacology · 30 Jul 2026 PMID 42532179
- Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy. Veterinary research communications · 25 Jun 2026 PMID 42348039
- Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. European journal of pain (London, England) · 5 Jun 2026 PMID 42248695
By study type
Observational studies and case reports (2)
- Long-Term Drop-Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox-Gastaut Syndrome. CNS neuroscience & therapeutics · 2 Nov 2026 PMID 42968542
- Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience. European journal of neurology · 26 Sept 2026 PMID 42798297
Human data, design not indexed (1)
- Systems medicine-driven drug repurposing for respiratory infections: insights into the oral-gut-lung microbial axis and the therapeutic potential of cannabidiol and aspirin. Theory in biosciences = Theorie in den Biowissenschaften · 14 Nov 2026 PMID 43033373
Preclinical: animal, cell and lab studies (14)
- Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma. Medical oncology (Northwood, London, England) · 26 Oct 2026 PMID 42932045
- Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of molecular medicine (Berlin, Germany) · 18 Sept 2026 PMID 42758182
- Toxic and repellent effects of hemp leaf extracts and cannabidiol against adult female yellow fever mosquitoes, Aedes aegypti. PloS one · 15 Sept 2026 PMID 42743102
- Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease. Metabolic brain disease · 3 Sept 2026 PMID 42690466
- Differential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood-Brain Barrier Integrity in a Rat Model of Iron Overload. Neurotoxicity research · 28 Aug 2026 PMID 42663810
- A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes. International journal of pharmaceutics · 25 Aug 2026 PMID 42641999
- Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
- Cannabidiol attenuates seizure progression and recognition memory deficit induced by hippocampal HCN1 knockdown in the kindling model of epilepsy in male rats. Neuropharmacology · 30 Jul 2026 PMID 42532179
- Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol. Drug delivery · 23 Jul 2026 PMID 42487275
- Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. PloS one · 20 Jul 2026 PMID 42475352
- Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy. Veterinary research communications · 25 Jun 2026 PMID 42348039
- Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion. AAPS PharmSciTech · 18 Jun 2026 PMID 42315741
- Microfluidics-Enabled Nanoparticle for Multiscale Synergetic Osteoarthritis Therapy. ACS nano · 9 Jun 2026 PMID 42261255
- Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. European journal of pain (London, England) · 5 Jun 2026 PMID 42248695
Unclassified: not yet indexed with MeSH (1)
- Mechanisms by which cannabidiol promotes peripheral nerve regeneration. Neural regeneration research · 20 Oct 2026 PMID 42899815
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-20 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.